28. Systemic amyloidosis Clinical trials / Disease details
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03678259 (ClinicalTrials.gov) | October 1, 2018 | 30/7/2018 | 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis | Evaluation of 124I-p5+14 Injection as an Imaging Agent for the Detection of Systemic Amyloidosis | Systemic Amyloidosis | Drug: 124I-p5+14 Injection | University of Tennessee Graduate School of Medicine | NULL | Completed | 18 Years | N/A | All | 57 | Phase 1/Phase 2 | United States |